Adherence can decrease hospitalizations for inflammatory bowel diseases

High-cost biologic therapies are associated with two-fold decrease in hospitalizations

August 21, 2019

Adherence to high-cost biologic therapies are associated with two-fold decrease in hospitalizations for key inflammatory bowel diseases

This study showed that members with Crohn’s disease or ulcerative colitis who were adherent to biologic therapy had approximately two-fold lower odds of hospitalization. Hospitalizations are costly from a direct and indirect cost perspective. To prevent one hospitalization through improved adherence, plans would incur substantial additional biologic therapy cost. It’s important to consider these findings in clinical care programs and as justification in value-based contracting.

Association Between Hospitalization for Crohn’s Disease (CD) or Ulcerative Colitis (UC) and Biologic Drug Therapy Adherence (March 2019)

Related news

Perspectives

September 25, 2023

Specialty Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

September 25, 2023

Traditional Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Perspectives

September 25, 2023

Gene/Cell Therapy Quarterly Update: September 2023

This quarterly pipeline wrap-up provides a review of newly approved gene and cell…